HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Symrise Touts Green, Biotech Developments In Scent & Care, Raises FY 2022 Growth Target

Executive Summary

Symrise AG is now projecting organic sales growth ‘significantly higher’ than 7%, versus a previous estimate of 5% to 7%. The German fragrance and flavors firm, which recorded a 10.2% increase in organic sales in the fiscal 2022 first half, pointed to Hydrolite 8 green and its partnership with biotech Evoxx Technologies among other innovation-minded moves to meet cosmetics demand.

You may also be interested in...



Arcaea CEO On Biotech’s Promise: Sustainable, Yes, But Ingredient Performance Will Drive Adoption

With biotech, “the entire tree of life starts to become accessible to us ethically and sustainably,” says Arcaea CEO Jasmina Aganovic. Her company, launched in October 2021, is developing custom keratin molecules for skin and hair, as well as new UV filter technology, among other innovations to expand formulators’ toolkits, not just replace problematic ingredients.

Revlon Gains $1.4Bn Financing From Subsidiaries, Appoints Interim CFO Amid Bankruptcy Fallout

Revlon approved for $1.4bn debtor-in-possession financing from BrandCo Lenders, a group of operating subsidiaries formed in capital structure changes which owns much of Revlon’s intellectual property. Firm appoints interim CFO to set course for debt restructuring.

E.l.f. Hoists 2023 Full-Year Sales Guidance As Value Prices Attract New Customers

E.l.f. Beauty’s sales grew 26% to $122.6m in the fiscal 2023 first quarter, leading the Oakland, CA-based firm to increase full-year projections. According to company leadership, e.l.f. is capturing market share at a rapid clip while expanding distribution, notably in pharmacy retail.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel